Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects diagnosed with spontaneous parkinsonism by the United Kingdom(UK) Parkinson's Disease Society Brain Bank criteria~* subjects who are able to explain symptoms they experience and to complete relevant assessment and exams including questionaires~* subjects who understand the purpose and protocols of the study and agree to participate on the study~Exclusion Criteria:~* subjects who experience psychiatrical disorders such as cognitive or behavioral disorders~* subjects who are on prokinetics or who are unable to cease such medication~* subjects who present neurological disorders which influence gastrointestinal mobility~* subjects who present gastrointestinal conditions which influence gastrointestinal mobility~* subjects with a history of gastrectomy or colectomy~* subjects who are unable to receive and complete the course of medication due to other metabolic disorders~* subjects diagnosed with parkinson plus syndrome~* subjects who are unable to undergo MRI scan for safety reasons due to claustrophobia or certain devices such as cardiac pacemakers or aneurysm clips

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DA-9701 (Type: EXPERIMENTAL): In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
- Domperidone (Type: ACTIVE_COMPARATOR): (This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).